Research Interests

My laboratory actively pursues the biochemical/molecular mechanisms underlying the role of eicosanoids (cysteinyl leukotrienes and prostaglandins) in inflammation, asthma and cancer. Our main goal is to develop novel eicosanoid (bioactive lipid)-based therapies for the treatment of cancer and cardiovascular diseases.

Current Research Projects

We focus on three specific areas of eicosanoid signaling, that have taken shape into three main projects and currently two of them have funding from the American Heart Association (AHA) and the NIH (R15).

  1. Cross-talk between leukotriene and other mediators in impacting mast cell function and inflammation. We mainly focus on novel synergism between leukotriene (LT)D4 and prostaglandin (PG)E2 signaling in peripheral and pulmonary inflammation and elucidation of the role of mast cells (MC) in inflammation
  2. CysLT2R as a therapeutic target for pathological angiogenesis, tumor progression and metastasis
  3. Mechano-sensitive ion channel, transient receptor potential vanilloid 4 (TRPV4) and PGE2 in matrix remodeling in asthma

Our research has the potential to move bench side research towards the development of novel therapeutic interventions for inflammation, asthma and cancer.

My laboratory has expertise with cutting edge cell and molecular biological techniques as well as mouse models of asthma and tumors. We employ knockout mouse models to tease out the contribution of individual receptors and proteins. We actively collaborate with faculty within Chemistry Department, other departments at the University of Akron, Northeast Ohio Medical University (NEOMED), Harvard Medical School and Summa Health Care System.


Our lab has generated several publications in high profile, peer reviewed journals. Our published work has been cited 1286 times and since 2011 it has been cited 787 times with an h-index and i10-index of 16 and 20 respectively (Google Scholar).

Selected Publications since 2011

  1. Kondeti V, Al-Azzam N, Duah E, Thodeti CK, Boyce JA, Paruchuri S*. (2016) Leukotriene D4 and prostaglandin E2 signals synergize and potentiate vascular inflammation in a mast cell–dependent manner through cysteinyl leukotriene receptor 1 and E-prostanoid receptor 3 J Allergy Clin Immunol. 137(1):289-98 (Impact factor: 12.4)

  2. Thoppil RJ, Cappelli HC, Adapala RK, Kanugula AK, Paruchuri S, Thodeti CK.( 2016) TRPV4 channels regulate tumor angiogenesis via modulation of Rho/Rho kinase pathway Oncotarget. doi: 10.18632/oncotarget.8405. [Epub ahead of print] PMID:27029071 (Impact factor: 6.3)

  3. Chanawanno K, Kondeti V, Caporoso J, Paruchuri S, Leeper TC, Herrick RS, Ziegler CJ. (2016) Facile rhenium-peptide conjugate synthesis using a one-pot derived Re(CO)3 reagent. Dalton Trans. 45(11):4729-35. PMID: 26863280 (Impact factor: 4.2)

  4. Adapala RK, Thoppil RJ, Ghosh K, Cappelli HC, Dudley AC, Paruchuri S, Keshamouni V, Klagsbrun M, Meszaros JG, Chilian WM, Ingber DE, Thodeti CK (2015) Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene. 21;35(3):314-22 (Impact factor: 8.5)

  5. Ham SL, Nasrollahi S, Shah KN, Soltisz A, Paruchuri S, Yun YH, Luker GD, Bishayee A, Tavana H (2015). Phytochemicals potently inhibit migration of metastatic breast cancer cells. Integr Biol (Camb). 7(7):792-800. (Impact factor: 4.0)

  6. Liu B, Pang Y, Bouhenni R, Duah E, Paruchuri S, McDonald L (2015). A step toward simplified detection of serum albumin on SDS-PAGE using an environment-sensitive flavone sensor. Chem Commun (Camb). 51(55):11060-3. PMID:26068596 (Impact factor: 6.8)

  7. Rahaman SO, Grove LM, Paruchuri S, Southern BD, Abraham S, Niese KA, Scheraga RG, Ghosh S, Thodeti CK, Zhang DX, Moran MM, Schilling WP, Tschumperlin DJ, Olman MA (2014) TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J Clin Invest.  124(12):5225-38 (Impact factor: 13.7)

  8. Al-Azzam N, Kondeti V, Duah E, Gombedza F, Thodeti CK, Paruchuri S*. (2014) Modulation of mast cell proliferative and inflammatory responses by Leukotriene D4 and Stem Cell Factor signaling interactions. J Cell Physiol. doi: 10.1002/jcp.24777. PMID:25161061  (Impact factor: 3.8)     

  9. Duah E, Adapala RK, Al-Azzam N, Kondeti V, Gombedza F, Thodeti CK, Paruchuri S*. (2013) Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors. Sci. Rep. (Nature Publishing Group) 3,3274; DOI:10.1038/srep03274. (Impact factor: 5.5)

  10. Kondeti V, Duah E, Al-Azzam N, Thodeti CK, Boyce JA, Paruchuri S*. (2013) Differential regulation of cysteinyl leukotriene receptor signaling by protein kinase          C in human mast cells PLoS One. 15;8(8):e71536. PMID:23977066 (Impact factor: 3.2)

  11. Wright BD, Deblock MC,  Wagers PO, Duah ED,  Robishaw NK, Shelton KL, Southerland MR, DeBord MA,             Kersten KM, McDonald LJ, Stiel JA, Panzner MJ, Tessier CA, Paruchuri S, Youngs, WJ (2015). Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines. Medicinal Chemistry Research 24(7). DOI:10.1007/s00044-015-1330-z (Impact factor: 1.6)